Improving the analgesic effectiveness of opioids while also reducing the adverse effects is a major goal of pain research.
One approach to this problem has been to combine drugs such as cannabinoids with opioids to determine if this might reduce the dose of opioid required to produce analgesia.
In this experiment, male nonhuman primates (rhesus macaques) were administered a range of doses of THC in combination with cumulative doses of heroin to determine if the combinations produced greater analgesia than that observed with heroin alone.
Briefly, the animals were secured in standard primate ch airs, tails were shaved, and dipped in a mixed order in three different water temperatures (40 °, 50 °, and 55 °C) until the animal rapidly withdrew his tail, or 20 seconds elapsed. Continue reading
Ketamine for Pain Management, Treatment of Depression – Linda Peckel – May 30, 2017
Ketamine may alleviate depression, pain, and side effects associated with opioid treatment, and may thus represent an attractive adjunct therapy for pain management, according to a novel population analysis recently published in Scientific Reports.
Nearly half of all patients with depression taking conventional antidepressants discontinue their treatment prematurely.
Researchers have sought alternatives to standard antidepressants, for which therapeutic effects are delayed by 2 to 10 weeks. Continue reading
Effective Opioids Declared Ineffective – by Zyp Czyk
In all the reporting about pain research, opioids are always declared ineffective for long-term chronic pain relief.
The full truth is that there have been NO long term studies and there is NO evidence proving they are INeffective either, but that isn’t mentioned.
This situation allows doctors and researchers to state only one side of the full truth, that there is no evidence opioids are effective and still feel like they are telling the “truth”.
This half-truth has created a nightmare scenario for pain patients: Continue reading
Successful management of neuropathic pain remains elusive despite the variety of pharmacologic classes prescribed to treat it, new research suggests.
Furthermore, the actual evidence supporting drugs used on an everyday basis is remarkably deficient, according to Richard W. Rosenquist, MD, the study’s author and chairman of the Department of Pain Management at the Cleveland Clinic, in Ohio
The Cleveland Clinic has become notorious for denying opioid pain medication to patients who desperately need them. Continue reading
Minimally Invasive SI Joint Fusion May Lessen Pain, Improve Quality of Life – Practical Pain Management – May 2017
Minimally invasive sacroiliac (SI) joint fusion was associated with significant improvements in pain relief and disability, as well as a decreased reliance on opioids, according to findings of a retrospective study published in Neurosurgery.
This study compared outcomes against conservative management (CM) or SI joint denervation, demonstrating that pain and disability levels returned to baseline levels with traditional approaches. Continue reading
Hyperalgesia: No Reason to Stop or Reduce Opioids – May 30, 2017 – by Forest Tennant M.D., Dr. P.H.
One of the excuses that some health practitioners are using to stop opioids is to claim a patient has hyperalgesia (HA).
This is a most dishonest, devious, and dangerous ploy.
First, the definition of hyperalgesia is simply that a stimulus such as hitting your thumb with a hammer is more painful than usual.
Second, there is no way to measure or quantify the presence of HA in a chronic pain patient who takes opioids. Continue reading
Recall of Zimmer Biomet’s Spinal Fusion Stimulators – May 31, 2017
Just when I thought electric stimulation could not possibly be damaging:
Zimmer Biomet has recalled the SpF PLUS-Mini and SpF XL IIb Implantable Spinal Fusion Stimulators due to higher than allowed levels of potential harmful chemicals,
“which may be toxic to tissues and organs, and that were found during the company’s routine monitoring procedure,” according to a release from the US Food and Drug Administration.
How are “harmful chemicals” released by an electric stimulator? Nowhere in the article are the specific “harmful chemicals” listed. Continue reading
Low Dose Vaporized Cannabis Significantly Improves Neuropathic Pain – J Pain. 2013 Feb – free full-text PMC article
Even back in 2013, research had already shown that cannabis can be effective for pain relief,.
We conducted a double-blind, placebo-controlled, crossover study evaluating the analgesic efficacy of vaporized cannabis in subjects, the majority of whom were experiencing neuropathic pain despite traditional treatment.
Thirty-nine patients with central and peripheral neuropathic pain underwent a standardized procedure for inhaling either medium dose (3.53%), low dose (1.29%), or placebo cannabis with the primary outcome being VAS pain intensity Continue reading
Many people do focused brain exercises to help develop their thinking. Some of these exercises work, while others do not. Regardless, the focus network in the brain is not the only network that needs training. The “unfocus” network needs training too.
The “unfocus network” (or default mode network)
Mu-Opioid Receptors on Nociceptors, Not Microglia, Drive Morphine Tolerance and Hyperalgesia in Mice | Pain Research Forum | by Matthew Soleiman – Feb 2017
By genetically removing mu-opioid receptors (MORs) from peripheral nociceptive neurons, the researchers found that they could reduce both tolerance and OIH while maintaining analgesia in mice receiving daily doses of morphine.
“The main take-away from the paper is that you can dissociate the side effects of opioids from the main effect of analgesia,”
What’s more, administration of morphine along with a peripherally restricted MOR antagonist also lessened tolerance and OIH without diminishing analgesia in models of perioperative and chronic pain. Continue reading